Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977457 · ClinicalTrials.gov registry record · Phase 1
Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery
A Phase 1 study of Prostate Cancer, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 1,045
- Enrollment target
- 1
- Study location
NCT00977457: Active Phase 1 study of Prostate Cancer, sponsored by City of Hope Medical Center.
NCT00977457 is a Phase 1 study of Prostate Cancer that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 1,045 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (72% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00977457, a Phase 1 study of Prostate Cancer, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,045 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies the side effects and best way to perform genetic testing in predicting biomarkers of recurrence in patients with prostate cancer undergoing surgery. Collecting and storing samples of tissue, blood, and other body fluids from patients to test in the laboratory and collecting information about the patient's health and treatment may help doctors learn more about cancer and help predict the recurrence of prostate cancer
Primary Outcome
Logistic regression and artificial neural networks will be used.
Conditions Studied
Interventions
- GENETIC gene expression analysis
- GENETIC polymerase chain reaction
- GENETIC DNA analysis
- GENETIC RNA analysis
- GENETIC DNA methylation analysis
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,045 participants |
| Start Date | 2007-11-26 |
| Est. Completion | 2026-07-08 |
| Phase | Phase 1 |
What the registry record for NCT00977457 still lists
NCT00977457 is an interventional study that assigns participants to a tested intervention. Its 1,045 participants enrollment target places it among the larger protocols in the corpus, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (72% higher).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00977457 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00977457 about?
NCT00977457 is a clinical study titled "Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery". This trial studies the side effects and best way to perform genetic testing in predicting biomarkers of recurrence in patients with prostate cancer undergoing surgery. Collecting and storing samples of tissue, blood, and other body fluids from patients to test in the laboratory and collecting inform...
What is the current status of trial NCT00977457?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1,045 participants. The study started on 2007-11-26. Estimated completion is 2026-07-08.
What conditions does trial NCT00977457 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00977457?
The interventions under investigation include: gene expression analysis (GENETIC), polymerase chain reaction (GENETIC), DNA analysis (GENETIC), RNA analysis (GENETIC), DNA methylation analysis (GENETIC).
Who is sponsoring clinical trial NCT00977457?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00977457 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00977457's enrollment target sits among peer trials
1,045 53rd of 735 higher than 683 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI